ABSTRACT
Background Immunotherapy with anti-PD-1 inhibitors has revolutionized the treatment of many solid tumors, however only 30-40% of patients will have a lasting clinical response. Tumor-derived extracellular vesicles (EVs) have been implicated in the spread of solid tumors and resistance to these agents. A lectin-affinity plasmapheresis device called the Hemopurifier (HP) has been developed and shown to remove extracellular vesicle in vitro and in patients. We hypothesize that the treatment of patients who are not improving on anti-PD-1 therapies will be safe, decrease EV concentrations, and improve anti-tumor T cell activity.
Methods This safety, feasibility and dose finding study is designed in a 3+3 safety study design with three treatment cohorts. Participants who are determined to be not responding to anti-PD-1 monotherapy will be assigned to receive either one, two, or three (HP) treatments over a one-week period prior to their next scheduled dose of anti-PD-1 antibody. Advancement from one cohort to the next will be determined by a DSMB. Data collection will include adverse events, safety labs, EV concentrations and T cell measurements, repeat imaging and survival status.
The primary outcome of the study will be the safety of the HP in this population with additional endpoints to include the kinetics of EV removal and rebound following HP treatment, in addition to the effects on T cell numbers and activity,
Ethics and dissemination The clinical protocol and amendment to the study protocol have been approved by the Ethics Committees and Research Governance Offices at three participating clinical sites in Australia. The Therapeutic Good Authority (TGA) has been notified. The clinical trial is listed on the Australia New Zealand Clinical Trials Registry. Informed Consent is obtained from all participants prior to any protocol procedures being performed.
Australia New Zealand Registration number ACTRN12624000732583
Competing Interest Statement
Authors SPL, AB, and RdNC are employees of Aethlon Medical, Inc who is funding the study described in the manuscript. Author NYK is a paid consultant to Aethlon Medical. Author GG has a contract with Aethlon Medical Australia PTY LTD to perform the central laboratory analyses for the study.
Clinical Trial
ACTRN12624000732583
Funding Statement
Funding for this study was provided by Aethlon Medical Australia PTY LTD
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Ethics Committee approval was obtained at Royal Adelaide Hospital as well as the Bellberry Human Research Ethics Committee for Pindara Private Hospital and Genesis Care/Royal North Shore Hospital
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding sources Funding for this study was provided by Aethlon Medical Australia PTY LTD
Conflict of interests Authors SPL, AB, and RdNC are employees of Aethlon Medical who is funding the study described in the manuscript. Author NY is a paid consultant to Aethlon Medical. Author GG has a contract with Aethlon Medical Australia PTY LTD to perform the central laboratory analyses for the study.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos